Literature DB >> 7515863

Peptidergic pathway in human skin and rat peritoneal mast cell activation.

M Mousli1, T E Hugli, Y Landry, C Bronner.   

Abstract

The common pathway of heterogenous mast cell activation as mediated by antigens is through the cross-linking of IgE bound to Fc epsilon RI receptors. The peptidergic pathway of mast cell activation, achieved by cationic secretagogues, is restricted to "serosal" mast cells, the experimental models being rat peritoneal and human skin mast cells. Cationic secretagogues include positively charged peptides but also various amines such as compound 48/80 and natural polyamines. An early intracellular event of this pathway is the activation of pertussis toxin-sensitive G proteins. The correlation observed between the ability of basic compounds to trigger mast cell exocytosis and their potency to activate purified G proteins strongly suggests that cationic compounds activate mast cell G proteins via a receptor-independent but membrane-assisted process. In this paper, alternative mechanisms are discussed. The consequence of G protein stimulation is the activation of phospholipase C with an increase in inositol triphosphates. Natural polyamines are relatively poor triggers of mast cells (10(-4) to 10(-2) M). Neuropeptides such as substance P, neuropeptide Y or vasoactive intestinal peptide, peptidic hormones such as kinins, and venoms such as mastoparan and mast cell degranulating peptide, are all active in a concentration range from 10(-7) to 10(-4) M. The cationic anaphylatoxin C3a also stimulates mast cells at concentrations below precursor complement C3 blood levels. The component C3 of the complement system is one of only a few plasma proteins having activation fragments (i.e. C3a) that can be generated at micromolar levels. The effects of basic secretagogues defines a peptidergic pathway of mast cell activation, which represents a potentially toxic process considering the tissue effects caused by exogenous basic compounds such as venom peptides and certain amine containing drugs. Peptidergic activation of mast cells may also be a pathophysiological process having an important role in neurogenic inflammation and in diseases involving extensive activation of the blood complement cascade.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515863     DOI: 10.1016/0162-3109(94)90002-7

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  24 in total

1.  Mast cell anaphylatoxin receptor expression can enhance IgE-dependent skin inflammation in mice.

Authors:  Beatrix Schäfer; Adrian M Piliponsky; Tatsuya Oka; Chang Ho Song; Norma P Gerard; Craig Gerard; Mindy Tsai; Janet Kalesnikoff; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2012-06-22       Impact factor: 10.793

2.  PMX-53 as a dual CD88 antagonist and an agonist for Mas-related gene 2 (MrgX2) in human mast cells.

Authors:  Hariharan Subramanian; Sakeen W Kashem; Sarah J Collington; Hongchang Qu; John D Lambris; Hydar Ali
Journal:  Mol Pharmacol       Date:  2011-03-11       Impact factor: 4.436

3.  Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation.

Authors:  Tony L Yaksh; Jeffery W Allen; Samantha L Veesart; Kjersti A Horais; Shelle A Malkmus; Miriam Scadeng; Joanne J Steinauer; Steve S Rossi
Journal:  Anesthesiology       Date:  2013-03       Impact factor: 7.892

4.  Involvement of tachykinin receptors in oedema formation and plasma extravasation induced by substance P, neurokinin A, and neurokinin B in mouse ear.

Authors:  H Inoue; N Nagata; Y Koshihara
Journal:  Inflamm Res       Date:  1996-07       Impact factor: 4.575

5.  Impact of actin rearrangement and degranulation on the membrane structure of primary mast cells: a combined atomic force and laser scanning confocal microscopy investigation.

Authors:  Zhao Deng; Tiffany Zink; Huan-yuan Chen; Deron Walters; Fu-tong Liu; Gang-yu Liu
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

6.  Significance of Conversation between Mast Cells and Nerves.

Authors:  Hanneke Pm van der Kleij; John Bienenstock
Journal:  Allergy Asthma Clin Immunol       Date:  2005-06-15       Impact factor: 3.406

7.  Inhibition by actinomycin D of neurogenic mouse ear oedema.

Authors:  H Inoue; N Nagata; Y Koshihara
Journal:  Inflamm Res       Date:  1995-03       Impact factor: 4.575

8.  Human beta-defensin-2 functions as a chemotactic agent for tumour necrosis factor-alpha-treated human neutrophils.

Authors:  François Niyonsaba; Hideoki Ogawa; Isao Nagaoka
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

9.  Mechanism of peptide-induced mast cell degranulation. Translocation and patch-clamp studies.

Authors:  D Lorenz; B Wiesner; J Zipper; A Winkler; E Krause; M Beyermann; M Lindau; M Bienert
Journal:  J Gen Physiol       Date:  1998-11       Impact factor: 4.086

10.  Mast cells: pivotal players in cardiovascular diseases.

Authors:  Ilze Bot; Theo J C van Berkel; Erik A L Biessen
Journal:  Curr Cardiol Rev       Date:  2008-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.